Short-term changes in magnetic resonance imaging and disease activity in response to infliximab

Annals of the Rheumatic Diseases

Volumn 69, Issue 1, 2010, Pages 120-125

  Bonel, H M ^a   Boller, C ^a   Saar, B ^a   Tanner, S ^a   Srivastav, S ^b   Villiger, P M ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b TULANE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INFLIXIMAB;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DISEASE ACTIVITY; FEMALE; HUMAN; IMAGE ANALYSIS; INFLAMMATION; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RATING SCALE; REMISSION; SIGNAL NOISE RATIO; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CONTRAST MEDIA; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; SPONDYLARTHRITIS; THORACIC VERTEBRAE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 73449125136     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.103200     Document Type: Article

References (23)

1. Calin A, Porta J, Fries JF, et al. Clinical history as a screening test for ankylosing spondylitis. JAMA 1977;237:2613-14.
2. Jenkinson TR, Mallorie PA, Whitelock HC, et al. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 1994;21:1694-8.
3. Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5.
4. Garrett S, Jenkinson T, Kennedy G, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
5. Braun J, Baraliakos X, Golder W, et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab. Evaluation of a new scoring system. Arthritis Rheum 2003;48:1126-36.
6. Treitl M, Korner M, Becker C, et al. Magnetic resonance imaging assessment of spinal inflammation in patients treated for ankylosing spondylitis. J Rheumatol 2008:35:128-36.
7. Baraliakos X, Listing J, Brandt J, et al. Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-α antibody infliximab. Rheumatology 2007;46:1450-3.
8. Sieper J, Baraliakos X, Listing J, et al. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab. Rheumatology 2005;44:1525-30.
9. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
10. Dougados M, van der Linden S, Juhlin R, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991;34:1218-27.
11. Bonel HM, Schneider P, Seemann MD, et al. MR imaging of the wrist in rheumatoid arthritis using gadobenate dimeglumine. Skeletal Radiol 2001;30:15-24.
12. Wolff D, Balaban RS. Assessing contrast on MR images. Radiology 1997;202:25-9.
13. Landis JR, Koch GG. An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers. Biometrics 1977;33:363-74.
14. Diarra D, Stolina M, Polzer K, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007;13:156-63.
15. LaSalle SP, Deodhar AA. Appropriate management of axial spondyloarthritis. Curr Rheumatol Rep 2007;9:375-82.
16. Baraliakos X, Listing J, Rudwaleit, et al. The relationship between inflammation and new bone formation in patients with AS. Arthritis Res Ther 2008;10:R104.
17. Brandt J, Haibel H, Cornely D, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 2000;43:1346-52.
18. Rudwaleit M, Baraliakos X, Listing J, et al. Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept. Ann Rheum Dis 2005;9:1305-10.
19. Haibel H, Rudwaleit M, Brandt HC, et al. Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. Arthritis Rheum 2006;54:678-81.
20. Braun J, Landewé R, Hermann KG, et al. ASSERT Study group: Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 2006;54:1646-52.
21. Braun J, Baraliakos X, Listing J, et al. Persistent clinical efficacy and safety of antitumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis 2008;67:340-5.
22. Stone M, Inman R. Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. J Rheumatol 2001;28:1605-14.
23. Rudwaleit M, Listing J. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor a blockers in ankylosing spondylitis. Ann Rheum Dis 2004;63:655-70.